First Time Loading...

Amicus Therapeutics Inc
NASDAQ:FOLD

Watchlist Manager
Amicus Therapeutics Inc Logo
Amicus Therapeutics Inc
NASDAQ:FOLD
Watchlist
Price: 10.33 USD -2.09% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

Amicus Therapeutics, Inc. operates as a biotechnology company. [ Read More ]

The intrinsic value of one FOLD stock under the Base Case scenario is 19.96 USD. Compared to the current market price of 10.33 USD, Amicus Therapeutics Inc is Undervalued by 48%.

Key Points:
FOLD Intrinsic Value
Base Case
19.96 USD
Undervaluation 48%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Amicus Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling FOLD stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Amicus Therapeutics Inc

Provide an overview of the primary business activities
of Amicus Therapeutics Inc.

What unique competitive advantages
does Amicus Therapeutics Inc hold over its rivals?

What risks and challenges
does Amicus Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Amicus Therapeutics Inc recently?

Summarize the latest earnings call
of Amicus Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Amicus Therapeutics Inc.

Provide P/S
for Amicus Therapeutics Inc.

Provide P/E
for Amicus Therapeutics Inc.

Provide P/OCF
for Amicus Therapeutics Inc.

Provide P/FCFE
for Amicus Therapeutics Inc.

Provide P/B
for Amicus Therapeutics Inc.

Provide EV/S
for Amicus Therapeutics Inc.

Provide EV/GP
for Amicus Therapeutics Inc.

Provide EV/EBITDA
for Amicus Therapeutics Inc.

Provide EV/EBIT
for Amicus Therapeutics Inc.

Provide EV/OCF
for Amicus Therapeutics Inc.

Provide EV/FCFF
for Amicus Therapeutics Inc.

Provide EV/IC
for Amicus Therapeutics Inc.

Show me price targets
for Amicus Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Amicus Therapeutics Inc?

How accurate were the past Revenue estimates
for Amicus Therapeutics Inc?

What are the Net Income projections
for Amicus Therapeutics Inc?

How accurate were the past Net Income estimates
for Amicus Therapeutics Inc?

What are the EPS projections
for Amicus Therapeutics Inc?

How accurate were the past EPS estimates
for Amicus Therapeutics Inc?

What are the EBIT projections
for Amicus Therapeutics Inc?

How accurate were the past EBIT estimates
for Amicus Therapeutics Inc?

Compare the revenue forecasts
for Amicus Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Amicus Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Amicus Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Amicus Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Amicus Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Amicus Therapeutics Inc with its peers.

Analyze the financial leverage
of Amicus Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Amicus Therapeutics Inc.

Provide ROE
for Amicus Therapeutics Inc.

Provide ROA
for Amicus Therapeutics Inc.

Provide ROIC
for Amicus Therapeutics Inc.

Provide ROCE
for Amicus Therapeutics Inc.

Provide Gross Margin
for Amicus Therapeutics Inc.

Provide Operating Margin
for Amicus Therapeutics Inc.

Provide Net Margin
for Amicus Therapeutics Inc.

Provide FCF Margin
for Amicus Therapeutics Inc.

Show all solvency ratios
for Amicus Therapeutics Inc.

Provide D/E Ratio
for Amicus Therapeutics Inc.

Provide D/A Ratio
for Amicus Therapeutics Inc.

Provide Interest Coverage Ratio
for Amicus Therapeutics Inc.

Provide Altman Z-Score Ratio
for Amicus Therapeutics Inc.

Provide Quick Ratio
for Amicus Therapeutics Inc.

Provide Current Ratio
for Amicus Therapeutics Inc.

Provide Cash Ratio
for Amicus Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Amicus Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Amicus Therapeutics Inc?

What is the current Free Cash Flow
of Amicus Therapeutics Inc?

Financials

Balance Sheet Decomposition
Amicus Therapeutics Inc

Current Assets 483.1m
Cash & Short-Term Investments 286.2m
Receivables 87.6m
Other Current Assets 109.2m
Non-Current Assets 294.8m
PP&E 58m
Intangibles 218.3m
Other Non-Current Assets 18.6m
Current Liabilities 167.7m
Accounts Payable 15.1m
Accrued Liabilities 152.6m
Non-Current Liabilities 450m
Long-Term Debt 387.9m
Other Non-Current Liabilities 62.2m
Efficiency

Earnings Waterfall
Amicus Therapeutics Inc

Revenue
399.4m USD
Cost of Revenue
-37.3m USD
Gross Profit
362m USD
Operating Expenses
-438.1m USD
Operating Income
-76.1m USD
Other Expenses
-75.5m USD
Net Income
-151.6m USD

Free Cash Flow Analysis
Amicus Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

FOLD Profitability Score
Profitability Due Diligence

Amicus Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROIC is Increasing
Positive 3-Years Revenue Growth
28/100
Profitability
Score

Amicus Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

FOLD Solvency Score
Solvency Due Diligence

Amicus Therapeutics Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Positive Net Debt
High D/E
31/100
Solvency
Score

Amicus Therapeutics Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

FOLD Price Targets Summary
Amicus Therapeutics Inc

Wall Street analysts forecast FOLD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FOLD is 19.13 USD with a low forecast of 14.14 USD and a high forecast of 23.1 USD.

Lowest
Price Target
14.14 USD
37% Upside
Average
Price Target
19.13 USD
85% Upside
Highest
Price Target
23.1 USD
124% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

FOLD Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

FOLD Price
Amicus Therapeutics Inc

1M 1M
-13%
6M 6M
+0%
1Y 1Y
-12%
3Y 3Y
+4%
5Y 5Y
-19%
10Y 10Y
+458%
Annual Price Range
10.33
52w Low
9.98
52w High
14.52
Price Metrics
Average Annual Return 14.36%
Standard Deviation of Annual Returns 77.8%
Max Drawdown -75%
Shares Statistics
Market Capitalization 3B USD
Shares Outstanding 295 383 008
Percentage of Shares Shorted 11.05%

FOLD Return Decomposition
Main factors of price return

What is price return decomposition?

FOLD News

Other Videos

Company Profile

Amicus Therapeutics Inc Logo
Amicus Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

3B USD

Dividend Yield

0%

Description

Amicus Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 496 full-time employees. The company went IPO on 2007-05-31. The firm's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.

Contact

PENNSYLVANIA
PHILADELPHIA
3675 Market Street
+12159217600.0
http://www.amicusrx.com/

IPO

2007-05-31

Employees

496

Officers

CEO, President & Director
Mr. Bradley L. Campbell M.B.A.
Chief Legal Officer & Corporate Secretary
Ms. Ellen S. Rosenberg
Chief People Officer
Mr. David M. Clark
Chief Development Officer
Dr. Jeffrey P. Castelli
Chief Financial Officer
Mr. Simon Nicolas Reade Harford
Chief Accounting Officer & Controller
Ms. Samantha Prout
Show More
Chief Science Officer
Dr. Jill Weimer Ph.D.
Senior Director of Investor Relations
Andrew Faughnan
Global Chief Compliance & Risk Officer
Mr. Patrik S. Florencio Esq.
Head of Global Corporate Communications
Ms. Diana Moore
Show Less

See Also

Discover More
What is the Intrinsic Value of one FOLD stock?

The intrinsic value of one FOLD stock under the Base Case scenario is 19.96 USD.

Is FOLD stock undervalued or overvalued?

Compared to the current market price of 10.33 USD, Amicus Therapeutics Inc is Undervalued by 48%.